Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes

European Journal of Immunology

Volumn 43, Issue 4, 2013, Pages 989-1000

  Hirayama, Michiko ^a   Nishikawa, Hiroyoshi ^a,b   Nagata, Yasuhiro ^c   Tsuji, Takemasa ^d   Kato, Takuma ^a   Kageyama, Shinichi ^a   Ueda, Shugo ^e   Sugiyama, Daisuke ^b   Hori, Sahoko ^a   Sakaguchi, Shimon ^b   Ritter, Gerd ^d   Old, Lloyd J ^d   Gnjatic, Sacha ^d   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Kitano Hospital   (Japan)

Author keywords

Cancer; Treg cells; Tumor immunology; Vaccination

Indexed keywords

CD4 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; PICIBANIL; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STREPTOCOCCUS PYOGENES; TUMOR IMMUNOLOGY; VACCINATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD4; ANTIGENS, NEOPLASM; CANCER VACCINES; EXUDATES AND TRANSUDATES; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-12; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MEMBRANE PROTEINS; NEOPLASMS; PICIBANIL; STREPTOCOCCUS PYOGENES; T-LYMPHOCYTES, REGULATORY;

EID: 84876444974     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242800     Document Type: Article

References (51)

1. Kawakami, Y. and Rosenberg, S. A., Human tumor antigens recognized by T-cells. Immunol. Res. 1997. 16: 313-339.
2. Scanlan, M. J., Gure, A. O., Jungbluth, A. A., Old, L. J. and Chen, Y. -T., Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 2002. 188: 22-32.
3. Boon, T., Coulie, P. G., Van den Eynde, B. J. and van der Bruggen, P., Human T cell responses against melanoma. Annu. Rev. Immunol. 2006. 24: 175-208.
4. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2002. 2: 389-400.
5. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004. 22: 531-562.
6. Nishikawa, H. and Sakaguchi, S., Regulatory T cells in tumor immunity. Int. J. Cancer 2010. 127: 759-767.
7. + regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010. 10: 490-500.
8. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 1999. 59: 3128-3133.
9. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999. 163: 5211-5218.
10. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. USA. 2003. 100: 10902-10906.
11. + regulatory T cells. J. Exp. Med. 2005. 201: 681-686.
12. + regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA. 2005. 102: 9253-9257.
13. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M. et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004. 10: 942-949.
14. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA. 2005. 102: 18538-18543.
15. Dannull, J., Su, Z., Rizzieri, D., Yang, B. K., Coleman, D., Yancey, D., Zhang, A. et al., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005. 115: 3623-3633.
16. Chen, Y.-T., Scanlan, M. J., Sahin, U., Tureci, O., Gure, A. O., Tsang, S., Williamson, B. et al., A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. U S A. 1997. 94: 1914-1918.
17. Gnjatic, S., Nishikawa, H., Jungbluth, A. A., Gure, A. O., Ritter, G., Jager, E., Knuth, A. et al., NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res. 2006. 95: 1-30.
18. Gnjatic, S., Nagata, Y., Jager, E., Stockert, E., Shankara, S., Roberts, B. L., Mazzara, G. P. et al., Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl. Acad. Sci. U S A. 2000. 97: 10917-10922.
19. Danke, N. A., Koelle, D. M., Yee, C., Beheray, S. and Kwok, W. W., Autoreactive T cells in healthy individuals. J. Immunol. 2004. 172: 5967-5972.
20. + helper T cell responses in cancer patients. Blood 2005. 106: 1008-1011.
21. + T cells following peptide vaccination. J. Immunol. 2006. 176: 6340-6346.
22. Iwasaki, A. and Medzhitov, R., Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004. 5: 987-995.
23. + T cell-mediated suppression by dendritic cells. Science 2003. 299: 1033-1036.
24. Sutmuller, R. P., den Brok, M. H., Kramer, M., Bennink, E. J., Toonen, L. W., Kullberg, B. J., Joosten, L. A. et al., Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 2006. 116: 485-494.
25. + regulatory T cells. Proc. Natl. Acad. Sci. USA. 2006. 103: 7048-7053.
26. Yang, Y., Huang, C. T., Huang, X. and Pardoll, D. M., Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 2004. 5: 508-515.
27. Nishikawa, H., Sato, E., Briones, G., Chen, L. M., Matsuo, M., Nagata, Y., Ritter, G. et al., In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J. Clin. Invest. 2006. 116: 1946-1954.
28. + T cells by bacterial vector. Blood 2008. 111: 1404-1412.
29. Nakahara, S., Tsunoda, T., Baba, T., Asabe, S. and Tahara, H., Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 2003. 63: 4112-4118.
30. Okamoto, M., Oshikawa, T., Tano, T., Ohe, G., Furuichi, S., Nishikawa, H., Ahmed, S. U. et al., Involvement of toll-like receptor 4 signaling in interferon-γ production and antitumor effect by streptococcal agent OK-432. J. Natl. Cancer Inst. 2003. 95: 316-326.
31. Okamoto, M., Oshikawa, T., Tano, T., Ahmed, S. U., Kan, S., Sasai, A., Akashi, S. et al., Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J. Immunother. 2006. 29: 78-86.
32. Ono, T., Harada, M., Yamada, A., Tanaka, M., Takao, Y., Tanaka, Y., Mine, T. et al., Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432. Clin. Cancer Res. 2006. 12: 1325-1332.
33. Oshikawa, T., Okamoto, M., Tano, T., Sasai, A., Kan, S., Moriya, Y., Ryoma, Y. et al., Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotheropeutic agent. J. Immunother. 2006. 29: 143-150.
34. Okamoto, M., Furuichi, S., Nishioka, Y., Oshikawa, T., Tano, T., Ahmed, S. U., Takeda, K. et al., Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 2004. 64: 5461-5470.
35. Rosenberg, S. A., Yang, J. C. and Restifo, N. P., Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004. 10: 909-915.
36. Dougan, M. and Dranoff, G., Immune therapy for cancer. Annu. Rev. Immunol. 2009. 27: 83-117.
37. Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F. and Lanzavecchia, A., Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 2005. 6: 769-776.
38. Warger, T., Osterloh, P., Rechtsteiner, G., Fassbender, M., Heib, V., Schmid, B., Schmitt, E. et al., Synergistic activation of dendritic cells by combined toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006. 108: 544-550.
39. - T cell activation in the presence of T regulatory cells. J. Immunol. 2005. 175: 641-645.
40. Zhao, J. X., Zhao, J. C. and Perlman, S., Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R. Plos One 2012. 7: e46241.
41. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 2005. 201: 723-735.
42. + Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009. 31: 772-786.
43. Wan, Y. S. Y. and Flavell, R. A., Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007. 445: 766-770.
44. Gnjatic, S., Altorki, N. K., Tang, D. N., Tu, S. M., Kundra, V., Ritter, G., Old, L. J. et al., NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin. Cancer Res. 2009. 15: 2130-2139.
45. Zhou, G., Drake, C. G. and Levitsky, H. I., Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006. 107: 628-636.
46. Bonertz, A., Weitz, J., Pietsch, D. H. K., Rahbari, N. N., Schlude, C., Ge, Y. Z., Juenger, S. et al., Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 2009. 119: 3311-3321.
47. Aoki, M., Ueda, S., Nishikawa, H., Kitano, S., Hirayama, M., Ikeda, H., Toyoda, H. et al., Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine 2009. 27: 6854-6861.
48. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl. Acad. Sci. U S A. 2003. 100: 8862-8867.
49. Stockert, E., Jager, E., Chen, Y.-T., Scanlan, M. J., Gout, I., Karbach, J., Arand, M. et al., A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 1998. 187: 1349-1354.
50. Riddell, S. R. and Greenberg, P. D., The use of anti-CD3 and anti-CD28 monoclonal-antibodies to clone and expand human antigen-specific T-cells. J. Immunol. Methods 1990. 128: 189-201.
51. Nagata, Y., Ono, S., Matsuo, M., Gnjatic, S., Valmori, D., Ritter, G., Garrett, W. et al., Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc. Natl. Acad. Sci. U S A. 2002. 99: 10629-10634.